Tianjin Medical Journal ›› 2023, Vol. 51 ›› Issue (3): 303-306.doi: 10.11958/20220813
• Clinical Research • Previous Articles Next Articles
TENG Lifeng1(), CHEN Xixi2, YE Cong1, HUANG Yubing1
Received:
2022-05-23
Revised:
2022-08-10
Published:
2023-03-15
Online:
2023-03-02
TENG Lifeng, CHEN Xixi, YE Cong, HUANG Yubing. Expression of serum Sestrin2 in acute ST-segment elevation myocardial infarction and its relationship with ischemia-reperfusion injury[J]. Tianjin Medical Journal, 2023, 51(3): 303-306.
CLC Number:
组别 | n | Sestrin2(μg/L) | MDA(μmol/L) | SOD(U/L) |
---|---|---|---|---|
对照组 | 50 | 6.53±2.01 | 3.97±1.05 | 98.87±15.87 |
STEMI组 | 124 | 10.36±3.18 | 5.32±1.56 | 72.32±13.12 |
t | 7.896** | 5.622** | 11.354** |
Tab.1 Comparison of serum Sestrin2, MDA and SOD levels between the control group and the STEMI group
组别 | n | Sestrin2(μg/L) | MDA(μmol/L) | SOD(U/L) |
---|---|---|---|---|
对照组 | 50 | 6.53±2.01 | 3.97±1.05 | 98.87±15.87 |
STEMI组 | 124 | 10.36±3.18 | 5.32±1.56 | 72.32±13.12 |
t | 7.896** | 5.622** | 11.354** |
组别 | n | 性别 (男/女) | 年龄 (岁) | 体质量指数 (kg/m2) | 高血压 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
非IRI组 | 52 | 32/20 | 57.17±8.51 | 22.12±1.49 | 31(59.62) | ||||||||||
IRI组 | 72 | 44/28 | 59.01±8.76 | 22.19±1.61 | 46(63.89) | ||||||||||
χ2或t | 0.002 | 1.168 | 0.246 | 0.234 | |||||||||||
组别 | 糖尿病 | 高脂血症 | 心绞痛史 | 发病到治疗 时间(h) | D to B (min) | ||||||||||
非IRI组 | 10(19.23) | 19(36.54) | 15(28.85) | 3.32±1.09 | 50.34±8.62 | ||||||||||
IRI组 | 18(25.00) | 28(38.89) | 24(33.33) | 3.69±1.28 | 53.04±9.25 | ||||||||||
χ2或t | 0.575 | 0.071 | 0.282 | 1.688 | 1.650 | ||||||||||
组别 | cTnI (μg/L) | LVEF | Sestrin2 (μg/L) | MDA (μmol/L) | SOD (U/L) | ||||||||||
非IRI组 | 19.86±4.52 | 0.63±0.07 | 7.84±2.67 | 4.53±1.29 | 79.95±14.96 | ||||||||||
IRI组 | 24.75±6.42 | 0.61±0.06 | 12.18±3.39 | 5.89±1.62 | 66.81±12.18 | ||||||||||
χ2或t | 4.711** | 1.707 | 7.670** | 5.012** | 5.383** |
Tab.2 Comparison of relevant indicators between the IRI group and the non IRI group
组别 | n | 性别 (男/女) | 年龄 (岁) | 体质量指数 (kg/m2) | 高血压 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
非IRI组 | 52 | 32/20 | 57.17±8.51 | 22.12±1.49 | 31(59.62) | ||||||||||
IRI组 | 72 | 44/28 | 59.01±8.76 | 22.19±1.61 | 46(63.89) | ||||||||||
χ2或t | 0.002 | 1.168 | 0.246 | 0.234 | |||||||||||
组别 | 糖尿病 | 高脂血症 | 心绞痛史 | 发病到治疗 时间(h) | D to B (min) | ||||||||||
非IRI组 | 10(19.23) | 19(36.54) | 15(28.85) | 3.32±1.09 | 50.34±8.62 | ||||||||||
IRI组 | 18(25.00) | 28(38.89) | 24(33.33) | 3.69±1.28 | 53.04±9.25 | ||||||||||
χ2或t | 0.575 | 0.071 | 0.282 | 1.688 | 1.650 | ||||||||||
组别 | cTnI (μg/L) | LVEF | Sestrin2 (μg/L) | MDA (μmol/L) | SOD (U/L) | ||||||||||
非IRI组 | 19.86±4.52 | 0.63±0.07 | 7.84±2.67 | 4.53±1.29 | 79.95±14.96 | ||||||||||
IRI组 | 24.75±6.42 | 0.61±0.06 | 12.18±3.39 | 5.89±1.62 | 66.81±12.18 | ||||||||||
χ2或t | 4.711** | 1.707 | 7.670** | 5.012** | 5.383** |
指标 | β | SE | Wald χ2 | P | OR | OR95%CI |
---|---|---|---|---|---|---|
cTnI | 0.267 | 0.201 | 1.765 | 0.184 | 1.306 | 0.881~1.937 |
Sestrin2 | 0.542 | 0.186 | 8.491 | 0.004 | 1.719 | 1.194~2.476 |
MDA | 0.368 | 0.174 | 4.473 | 0.034 | 1.445 | 1.027~2.032 |
SOD | -0.645 | 0.248 | 6.764 | 0.009 | 0.525 | 0.323~0.853 |
常数项 | 0.205 | 0.103 | 3.961 | 0.047 | 1.228 | - |
Tab.3 Analysis of risk factors for IRI in STEMI patients
指标 | β | SE | Wald χ2 | P | OR | OR95%CI |
---|---|---|---|---|---|---|
cTnI | 0.267 | 0.201 | 1.765 | 0.184 | 1.306 | 0.881~1.937 |
Sestrin2 | 0.542 | 0.186 | 8.491 | 0.004 | 1.719 | 1.194~2.476 |
MDA | 0.368 | 0.174 | 4.473 | 0.034 | 1.445 | 1.027~2.032 |
SOD | -0.645 | 0.248 | 6.764 | 0.009 | 0.525 | 0.323~0.853 |
常数项 | 0.205 | 0.103 | 3.961 | 0.047 | 1.228 | - |
指标 | AUC(95%CI) | 敏感度 (%) | 特异度 (%) | 约登 指数 | 截断值 |
---|---|---|---|---|---|
Sestrin2 | 0.759(0.673~0.845) | 76.39 | 67.31 | 0.437 | 9.41 μg/L |
MDA | 0.654(0.557~0.751) | 56.94 | 73.08 | 0.300 | 5.28 μmol/L |
SOD | 0.671(0.575~0.767) | 84.72 | 44.23 | 0.290 | 71.78 U/L |
Tab.4 Analysis of predictive value of serum Sestrin2, MDA and SOD for IRI in STEMI patients
指标 | AUC(95%CI) | 敏感度 (%) | 特异度 (%) | 约登 指数 | 截断值 |
---|---|---|---|---|---|
Sestrin2 | 0.759(0.673~0.845) | 76.39 | 67.31 | 0.437 | 9.41 μg/L |
MDA | 0.654(0.557~0.751) | 56.94 | 73.08 | 0.300 | 5.28 μmol/L |
SOD | 0.671(0.575~0.767) | 84.72 | 44.23 | 0.290 | 71.78 U/L |
[1] | FRAMPTON J, DEVRIES J T, WELCH T D, et al. Modern management of ST-segment elevation myocardial infarction[J]. Curr Probl Cardiol, 2020, 45(3):100393. doi:10.1016/j.cpcardiol.2018.08.005. |
[2] | LYU S, LIU H, WANG H. The interplay between autophagy and NLRP3 inflammasome in ischemia/reperfusion injury[J]. Int J Mol Sci, 2021, 22(16):8773. doi:10.3390/ijms22168773. |
[3] | PICKELL Z, WILLIAMS A M, ALAM H B, et al. Histone deacetylase inhibitors:a novel strategy for neuroprotection and cardioprotection following ischemia/reperfusion injury[J]. J Am Heart Assoc, 2020, 9(11):e016349. doi:10.1161/JAHA.120.016349. |
[4] | PANISELLO-ROSELLO A, ROSELLO-CATAFAU J. Molecular mechanisms and pathophysiology of ischemia-reperfusion injury[J]. Int J Mol Sci, 2018, 19(12):4093. doi:10.3390/ijms 19124093. |
[5] | KISHIMOTO Y, KONDO K, MOMIYAMA Y. The protective role of sestrin2 in atherosclerotic and cardiac diseases[J]. Int J Mol Sci, 2021, 22(3):1200. doi:10.3390/ijms22031200. |
[6] | 郭明, 赵博, 雷少青, 等. Sestrin2/一磷酸腺苷活化的蛋白激酶介导的细胞自噬在糖尿病大鼠心肌缺血再灌注损伤中的作用及叔丁基对苯二酚预处理的保护作用[J]. 中华糖尿病杂志, 2017, 9(6):382-387. |
GUO M, ZHAO B, LEI S Q, et al. Sestrin2/adenosine monophosphate activated protein kinase regulated autophagy pathway in myocardial ischemia-reperfusion injury in diabetic rats and the protective effect of tert-butyl hydroquinone[J]. Chin J Diabet, 2017, 9(6):382-387. doi:10.3760/cma.j.issn.1674-5809.2017.06.010. | |
[7] | 中华医学会心脏病学会, 中国心脏病学杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南(2019)[J]. 中华心血管病杂志, 2019, 47(10):766-783. |
SOCIETY OF CARDIOLOGY, C M A,EDITORIAL BOARD OF CHIN J CARDIOL. 2019 Chinese Society of Cardiology(CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction[J]. Chin J Cardiol, 2019, 47(10):766-783. doi:10.3760/cma.j.issn.0253-3758.2019.10.003. | |
[8] | 张英, 王亚柱, 张皓然, 等. 心肌缺血再灌注损伤不同表现形式的临床研究[J]. 中国医药导报, 2019, 16(23):64-68. |
ZHANG Y, WANG Y Z, ZHANG H R, et al. Clinical study on different manifestations of myocardial ischemia-reperfusion injury[J]. Chin Med Herald, 2019, 16(23):64-68. | |
[9] | BHATT D L, LOPES R D, HARRINGTON R A. Diagnosis and treatment of acute coronary syndromes:A review[J]. JAMA, 2022, 327(7):662-675. doi:10.1001/jama.2022.0358. |
[10] | ZHENG J, CHEN P, ZHONG J, et al. HIF-1α in myocardial ischemia-reperfusion injury(Review)[J]. Mol Med Rep, 2021, 23(5):352. doi:10.3892/mmr.2021.11991. |
[11] | ZHANG M L, PENG W, NI J Q, et al. Recent advances in the protective role of hydrogen sulfide in myocardial ischemia/reperfusion injury:a narrative review[J]. Med Gas Res, 2021, 11(2):83-87. doi:10.4103/2045-9912.311499. |
[12] | WANG P, ZHAO Y, LI Y, et al. Sestrin2 overexpression attenuates focal cerebral ischemic injury in rat by increasing Nrf2/HO-1 pathway-mediated angiogenesis[J]. Neuroscience, 2019, 410(7):140-149. doi:10.1016/j.neuroscience.2019.05.005. |
[13] | SUN W, WANG Y, ZHENG Y, et al. The emerging role of sestrin2 in cell metabolism, and cardiovascular and age-related diseases[J]. Aging Dis, 2020, 11(1):154-163. doi:10.14336/AD.2019.0320. |
[14] | CHE X, CHAI J, FANG Y, et al. Sestrin2 in hypoxia and hypoxia-related diseases[J]. Redox Rep, 2021, 26(1):111-116. doi:10.1080/13510002.2021.1948774. |
[15] | PAN C, CHEN Z, LI C, et al. Sestrin2 as a gatekeeper of cellular homeostasis:physiological effects for the regulation of hypoxia-related diseases[J]. J Cell Mol Med, 2021, 25(12):5341-5350. doi:10.1111/jcmm.16540. |
[16] | 庞旭阳, 郝晓静, 郭宏盛, 等. 急性缺血性脑卒中患者血清PRDX1、Sestrin2水平与病情及预后的关系[J]. 中国现代医学杂志, 2021, 31(9):51-55. |
PANG X Y, HAO X J, GUO H S, et al. Correlation of serum Sestrin 2 and PRDX1 with prognosis of patients with acute ischemic stroke[J]. Chin J Mod Med, 2021, 31(9):51-55. doi:10.3969/j.issn.1005-8982.2021.09.010. | |
[17] | 刘英存, 李飞, 黄毅, 等. Sestrin2蛋白通过Nrf2/HO-1信号通路保护大鼠心肌细胞缺氧复氧损伤[J]. 第三军医大学学报, 2020, 42(15):1536-1542. |
LIU Y C, LI F, HUANG Y, et al. Sestrin2 protects rat cardiomyocytes from hypoxia-reoxygenation injury through Nrf2/HO-1 signaling pathway[J]. Acta Acad Med Mil Tert, 2020, 42(15):1536-1542. doi:10.16016/j.1000-5404.202003201. |
[1] | WANG Xinshuang, AN Yajuan, GUAN Xiuju, LI Jiao, LIU Yue, WEI Liping, QI Xin. Study of magnesium isoglycyrrhizinate in ameliorating cisplatin induced myocardial injury in rats [J]. Tianjin Medical Journal, 2024, 52(8): 809-814. |
[2] | WU Bo, ZHU Zhuonong, ZHENG Lijuan, CHEN Junru. Effects of matrine on inflammation, oxidative stress and wound healing in atopic dermatitis [J]. Tianjin Medical Journal, 2024, 52(6): 566-571. |
[3] | LI Min, GONG Jian, WU Weiwei, LIU Qiao. Research progress on the role of Nrf2/HO-1 pathway in psoriasis [J]. Tianjin Medical Journal, 2024, 52(5): 552-556. |
[4] | XIE Youcheng, WANG Fei, XU Jin, YU Xiaohui. Research progress of SIRT1 in the pathogenesis of diabetic cardiomyopathy [J]. Tianjin Medical Journal, 2024, 52(4): 443-448. |
[5] | CHEN Jing, WEI Yunjiao, LUO Chao, HUANG Lihua, CHEN Cheng, DUAN Shasha. The mechanism of Wumei pill on ulcerative colitis in mice based on Nrf2/ARE antioxidant stress pathway [J]. Tianjin Medical Journal, 2024, 52(3): 278-254. |
[6] | HAO Jianling, XIN Jingjing, WANG Jing, TIAN Hong, SU Haitao. Effect of phillyrin regulating NLRP3 inflammatory pathway on exudates and lung injury in rats with acute pleurisy [J]. Tianjin Medical Journal, 2024, 52(2): 161-166. |
[7] | ZHANG Xiaoxu, YANG Wenqi. Clinical study of sacubitril valsartan in the treatment of patients with heart failure of midrange ejection fraction after acute myocardial infarction [J]. Tianjin Medical Journal, 2024, 52(2): 177-181. |
[8] | MIAO Chunbo, XU Yingchun, CHANG Yifang. Phlorizin allevistes oxidative stress and apoptosis of rat cardiac myocytes H9C2 induced by hypoxia/reoxygenation by down-regulating miR-125a-5p [J]. Tianjin Medical Journal, 2024, 52(12): 1233-1238. |
[9] | CAI Dengta, CHANG Jingyi, JIA Shanshan, TU Yinqiong. Roxadustat improves myocardial ischemia-reperfusion injury in mice by inhibiting apoptosis and inflammatory response [J]. Tianjin Medical Journal, 2024, 52(11): 1146-1151. |
[10] | ZHANG Jinwu, XIE Dingling, CHEN Li. The effect of securinine on neurological function recovery after cerebral ischemia-reperfusion injury in rats [J]. Tianjin Medical Journal, 2023, 51(9): 977-982. |
[11] | CHEN Xilong, WANG Hongjun, SONG Zhengyu, WANG Jing. Arctigenin alleviates neuronal damage of acute cerebral infarction in rats by inhibiting the HMGB1/TLR4/NF-κB pathway [J]. Tianjin Medical Journal, 2023, 51(8): 825-829. |
[12] | SHI Jiaxin, LI Nuo, YANG Yegui, FANG Wei, QIN Sina, HUANG Jingju, CHEN Menghua. Moderately elevating blood potassium concentration can improve mitochondrial function of brain tissue in cardiopulmonary resuscitation rats [J]. Tianjin Medical Journal, 2023, 51(7): 724-728. |
[13] | TIAN Yajing, YANG Xue, WANG Jing, GE Wenjie, HE Yuling. Influence of formononetin on oxidative stress injury in gestational diabetes mellitus rats [J]. Tianjin Medical Journal, 2023, 51(7): 734-738. |
[14] | WANG Xiaohong, QIAN Jing, WANG Jiawei, QI Xiaoming, MENG Yun, WANG Ping, CHENG Ruizhi, ZHOU Guoxiong. The study on the mechanism of salidroside in the adjuvant treatment of patients with moderately severe acute pancreatitis [J]. Tianjin Medical Journal, 2023, 51(7): 762-765. |
[15] | LI Yanping, WANG Xietao, SHI Libin, LIU Qiong. Influence of resveratrol on H2O2-induced ferroptosis in alveolar epithelial cells by regulating the Nrf2-GPX4 pathway [J]. Tianjin Medical Journal, 2023, 51(6): 568-572. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||